IMIDomics, Bristol Myers Squibb to research Sjögren's disease, atopic dermatitis

Key takeaways:

• IMIDomics and Bristol Myers Squibb entered a partnership to research immune-mediated inflammatory diseases.
• An expansion of this partnership will now include Sjögren's syndrome and atopic dermatitis research.

IMIDomics and Bristol Myers Squibb have expanded their partnership to include Sjögren's syndrome and atopic dermatitis in their research and development efforts for inflammatory diseases, the companies announced in a press release.

The companies initially entered a partnership in 2016 to advance research and development for new treatments for immune-mediated inflammatory diseases (IMIDs). These diseases include ulcerative colitis, Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, psoriasis and systemic lupus erythematosus.

“Bristol Myers Squibb has been a critical partner for IMIDomics over the past several years and we are thrilled to continue working together to tackle the challenges faced by those living with IMIDs,” Sara Marsal, MD, PhD, chief medical officer of IMIDomics, said in the release. “This expanded collaboration will allow both companies to accelerate IMID research using our Clinical Discovery Engine to better understand and uncover mechanisms driving Sjögren's syndrome and atopic dermatitis.”

IMIDomics’ Clinical Discovery Engine is a system that integrates and analyzes comprehensive epidemiological, clinical and multi-omic biomolecular data from patients with IMIDs. Through this collaboration, the companies plan to use these data to further understand and develop new treatment options for these diseases.